Scholar Rock (SRRK) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
16 Nov, 2026U.S. launch and demand
Eight weeks after mid-September 2026 U.S. approval, demand was described as solid, broad and steady week to week, spanning adults and children, varied disease trajectories and existing SMN therapies.
FDA label covers patients age 2+ receiving an SMN2-targeted therapy; estimated U.S. eligible population ~6,600.
98% of enrolled patients joined Scholar Rock Supports; treatment-naive enrollments exceeded patients previously treated through EAP or ONYX studies.
More than one-third of the top 140 U.S. SMA centers had submitted enrollment forms by end-October; demand also reached centers outside the top 140.
Muscle strength ranked as the top need in the 2026 Cure SMA survey; three-quarters of neurologists recognized the rationale for targeting both motor neurons and muscle.
Reimbursement and clinical evidence
Initial prescription-to-infusion timing was typically 60–90 days or more at launch, with management expecting the interval to shorten as launch processes mature; annual re-verification may still apply.
Anthem and Centene published medical policies aligned with the label, representing 47 million covered lives; some patients had already started infusions.
A J-code was planned for April 1; coverage policies and the code were expected to support more consistent reimbursement and access.
In SAPPHIRE, add-on apitegromab showed a 2.2-point Hammersmith motor-function improvement and nearly 4x greater likelihood of a 3-point-or-more improvement versus placebo.
International expansion
EMA application was resubmitted and validated with an alternate fill-finish facility; CHMP opinion expected in H1 2027, followed by a German launch in H2 2027.
Japan’s JNDA was accepted for priority review; a ~9-month review plus 60–90 days of pricing discussions could enable launch in late 2027.
Global plans include Europe, Japan and up to 50 countries; a German team was ready and Tokyo operations had been established.
Management viewed MFN as a minimal concern, citing the rare-disease profile and plans for a narrow global price; the SMA drug category generated well over $5B in annual revenues, with 64% outside the U.S.
Latest events from Scholar Rock
- Broad early ISEMBYLD demand sets up U.S. expansion, global launches, and pipeline growth.SRRK
Jefferies Global Healthcare Conference - ISEMBYLD launched with $0.57M in Q3 revenue as access and global expansion advance.SRRK
Q3 2026 - FDA approves ISEMBYLD, the first muscle-targeted SMA therapy, with immediate U.S. launch.SRRK
FDA announcement - Apitegromab set for 2026 launch as first muscle-targeted SMA therapy, driving global expansion.SRRK
Corporate presentation - Apitegromab nears FDA approval as a first-in-class SMA therapy, with global launch plans underway.SRRK
Citigroup’s Biopharma Back to School Summit 2026 - FDA decision on apitegromab for SMA expected by September 30, with global launches planned.SRRK
12th Annual Cantor Fitzgerald Global Healthcare Conference - Apitegromab nears FDA approval with dual manufacturing paths and strong launch readiness.SRRK
Canaccord Genuity's 46th Annual Growth Conference - FDA decision on apitegromab expected by September 30, 2026, with strong cash reserves and launch readiness.SRRK
Q2 2026 - Apitegromab plus tirzepatide preserved lean mass and improved weight loss quality in obesity.SRRK
Study Update